Grand Hyatt Shanghai New Growth Models For China

Grand Hyatt Shanghai New Growth Models For China At the PharmAsia Summit Shanghai, Elsevier and BayHelix will focus on new R&D and commercial models in a rapidly changing China. Given demographic changes and China's massive health care reforms, opportunities abound - but so do potential pitfalls. Tapping the unmet medical need present in China provides Pharma with one of its few growth bright spots. But achieving this growth will require new models and flexibility: smaller cities are now growing faster than Tier I cities presenting logistical challenges; off-patent medications are under severe pricing pressure, which could limit the widespread uptake of branded generics. While support for biopharma innovation is a major government goal, so is curbing healthcare inflation. How can Pharmas collaborate and thrive in this environment? At the PharmAsia Summit, top industry leaders from China and the West will discuss new growth models for China via a series of case studies, panels and keynotes. To kick-off the Summit, we will release our 2 nd annual PharmAsia Summit Report, an in-depth analysis of trends critical to biopharmaceutical development and commercialization in the China market, authored by our knowledge partner, McKinsey & Co. Inc. The agenda for the PharmAsia Summit is developed by an organizing committee chaired by Steve Yang, PhD, VP, Head of Asia and Emerging Markets imed, AstraZeneca PLC. Presented By Knowledge Partner

Agenda to Date (subject to change) Simultaneous translation will be provided throughout the conference 12:00-12:50 Registration 12:50PM Welcome and Opening Remarks 1:00-2:00PM Roundtable 1 2:00-2:30PM 2:30-3:30PM 3:30-4:00PM 4:00-5:00PM Networking Break Therapeutic Spotlight: Opportunities and Challenges in China s Oncology Market Sponsored by Kantar Health Networking Break Doing Business Development in China Today: An Analysis of Top Deal Structures Sponsored by Navigant Paul Zhang Managing Director, Life Sciences Navigant Sundeep Lal, PhD VP, Strategy, Business Development & Business Model Innovation Medtronic 5:00-6:15PM Opening Plenary Session: Presentation of the 2013 PharmAsia Summit China Report In our opening plenary, McKinsey & Co., Elsevier and BayHelix will discuss findings from our exclusive report on how to enable innovation and drive growth in China in an environment of intensifying cost pressure. Conference attendees will receive a complimentary copy of the report. Franck LeDeu Leader of Greater China Healthcare Practice McKinsey & Co. Inc. Jimmy Zhang, PhD Greater China Lead, Licensing, Acquisitions, and External Research Merck & Co. Inc.

6:15-8:00PM Welcome Reception 7:30-8:30AM Breakfast Networking & Facilitated Discussions Want another chance to interact with other attendees and speakers? These breakfast discussions are an excellent way to discuss and learn about industry challenges, and each will be led by a China pharma expert. Each table is limited to 10 people; first come, first serve. Sign-up sheets will be available onsite. Choose to participate in one of several facilitated discussions on key topics facing the industry. 1. The Commercial Challenge 2. The R&D Challenge, facilitated by Franck LeDeu, McKinsey & Co. 3. The Regulatory Challenge 4. The Payer Challenge 5. The Funding Challenge 6. The BD Challenge 8:30-8:45AM Welcome, Elsevier and Bay Helix Opening Remarks & Meeting Overview Franck LeDeu Leader of Greater China Healthcare Practice McKinsey & Co. Inc. 8:45 9:30AM KEYNOTE ADDRESS Fueling Roche s Growth: The Importance of the Asia Pacific Region Luke Miels Regional Head, Asia Pacific Roche Singapore Pte Ltd.

9:30-10:45AM KEYNOTE PANEL Defining A China-based Innovation Strategy: Should Early Stage R&D Be A Priority? The question was never if China would produce innovative products but when and what kind. As the market in China evolves, the notion of innovation is changing. Skeptics wonder if R&D groups have the internal capabilities required to translate early stage science into novel pharmaceutical products and whether the Chinese government will pay for them if they do. Instead of trying to create a second-wave of Eastern-researched blockbusters, why not focus on health care services and fast-follower molecules, tailored to the huge unmet medical needs that exist in the country today? In this session, heads of China R&D from multinationals and domestic companies discuss the R&D opportunities that make the most sense now. Steve Yang, PhD VP, Head of Asia and Emerging Markets imed AstraZeneca Liangshang Zhang, PhD President of Global R&D Jiangsu Hengrui Medicine James Garner, MD Vice President and Global Manager Takeda Global Research and Development Center (Asia) Henry Sun, PhD President and CEO Tasly Pharmaceuticals Inc. 10:45 11:15AM Networking Break

11:15-12:15PM The New Goldrush: Biologics Investment in China Improving infrastructure, government funding, and local demand for products to treat complex diseases are driving private equity investment in China s nascent biologics sector. But the dearth of manufacturing capacity, the challenging regulatory environment, weak IP protection, and still developing R&D capabilities cause some to wonder just how golden is China s biologics opportunity? Panel participants will discuss how best to leverage China s growing biologics capabilities and resources while minimizing the execution challenges. Racho Jordanov President and CEO JHL Biotech Michael Yu, PhD President and CEO Innovent Biologics Inc. Jeremy Caudill Global Vice President Business Development Samsung Biologics

12:15-1:15PM Regulatory Insight: Strategies to Accelerate the Time To Market SFDA s so-called Green Channel allows drug sponsors to formally consult with the regulatory body in an effort to speed up the notoriously slow China drug approvals process. Now SFDA, and its successor CFDA, appears ready to take the channel one step further, proposing a parallel system that simultaneously reviews investigational new drug applications and ethical committee evaluations. In this panel discussion we review not just the current workings of the Green Channel, but other strategies, including joint venture structures and Asia-based clinical trial designs, which multi-nationals can use to accelerate the development time line to launch products more rapidly in China. Ling Su, PhD (moderator) Strategic Advisor, Life Sciences Sidley Austin LLP George Yeh President Taiwan Liposome Company Ltd. Benny Li, PhD Vice President and Head of Development Takeda Pharmaceuticals China Ruilin Song Executive President SINO-PhIRDA 1:15-2:30PM Lunch + Elsevier-Bay Helix Awards Ceremony 1. R&D Achievement Of The Year 2. Alliance Of The Year 3. Commercial Achievement Of The Year 4. R&D Leadership Award

2:30-3:30PM Debate: What s Needed Now To Support Early Stage China Biotechs Perhaps the biggest challenge facing early stage biotechs in China is the dearth of private equity to finance them. This capital dry spell has VCs and execs worried that the U.S. s famed Valley of Death is rapidly sickening China-based biotechs as well. Skeptics scoff, likening such talk to Chicken Little s claim that the sky is falling. They argue the lack of available financing is explained by a simpler reason: there just aren t many new opportunities that are scientifically compelling and can deliver the needed ROI. In this hour-long session, top executives will debate strategies that are best suited to move early stage biotechs to the growth phase of their life cycles. Kewen Jin, PhD (moderator) Managing Director Nimbus Innoworks John Oyler Founder and CEO BeiGene Ltd. Jonathan Wang, PhD Senior Managing Director OrbiMed Samantha Du, PhD Managing Director Sequoia Capital China Carl Firth, PhD CEO Aslan Pharmaceuticals 3:30-4:15PM KEYNOTE ADDRESS At the Intersection of Drug Distribution and Health Care Policy: The View from Cardinal China Eric Zwisler President, China Cardinal Health China 4:15-4:30PM Networking Break

4:30-5:45PM BD in China: Why Now Is The Time To Partner With Domestics (PAS/PSA Showcase Panel) Government reform initiatives, pricing pressures, and slowing growth in Tier 1 cities make it difficult for multinationals to sustain their current China growth rates organically. To succeed, MNCs have sought alliances with Chinese domestic pharmas to access their commercial channels and are changing their approaches to partnering in the region. At the same time China-based entities are making inroads in their quest for access to innovative molecules and platforms, including presenting internally developed assets to US regulators. In this panel discussion, you ll hear from experts at multinationals and domestic outfits about deal-making in today s China, not only with each other, but with parties seeking to access new capabilities across the value chain. What kinds of alliances are today s hottest China-based deal makers most interested in pursuing? What deal structures work best to promote a given strategy? Debra Yu, MD (moderator) Managing Director Labrador Advisors Jimmy Zhang, PhD Greater China Lead, Licensing, Acquisitions & External Research, WW Licensing & Acquisitions Merck & Co., Inc. Jun Bao, PhD Senior Vice President and Chief Business Officer Shenogen Pharma Group Ltd. Sophie Kornowski-Bonnet Head of Roche Partnering Roche Sam Hua Jiang Vice President (International Business) Luye Pharma Group Philip Fang Business Development Director China Resources Pharmaceutical Group Ltd. 6:00PM Cocktail Reception

7:30-8:30AM 8:30-8:45AM Breakfast Networking Welcome Back and Recap Franck LeDeu Leader of Greater China Healthcare Practice McKinsey & Co. Inc. 8:45-9:30AM KEYNOTE ADDRESS 9:30-10:30AM Sanofi s APAC Strategy: The Strategic Importance of China Jean-Luc Lowinski, PhD SVP Asia Region Sanofi Bridging the Affordability Gap: Improving Market Access To High-Priced Therapeutics As China s middle class hungers for access to high-priced medicines designed to treat severe diseases like cancer, multinationals can t rely completely on traditional mechanisms like patient assistance programs. One solution: work with local insurers to design supplemental commercial insurance that patients can tap if they need medicines that aren t listed on the National Drug Reimbursement List. It s a strategy that s been highly successful for Roche, which saw its China-based product sales skyrocket 27% in 2012. Alternatively, there s the opportunity to partner with wealthier provinces to reimburse therapies in high priority diseases, particularly liver, lung, and gastric cancer. In exchange for patient volume, biopharmas would provide provincial governments with significant rebates and patient assistance. This panel highlights innovative experiments designed to bridge China s affordability gap. Paul Zhang (moderator) Managing Director Navigant Harald Sprenger Director Access Asia-Pacific Roche Pharmaceuticals Howard Gough Managing Director, CGHB, Asia Pacific CIGNA

10:30-11:00AM 11:00-12:15PM Networking Break Pricing Pressure: Winning Strategies In An Era Of Cost Containment There s always been an art to pricing pharmaceutical products; in China, however, this artistry reaches new heights. A national pricing scheme sets maximum retail prices for reimbursed drugs, and then mandates periodic cuts. At the provincial level, China s 31 provinces have competitive tenders, each with their own rules to determine the value of a drug. Inter-provincial reference pricing and hospital protocols that require formulary listing or cap annual reimbursement further complicate the process. To top it off, China recently expanded its Essential Drug List (EDL) to cover more than 500 new products, including off-patent China blockbusters. Against this backdrop, pharma companies are testing new strategies to thrive in an era of increasing cost pressures. Franck Le Deu (moderator) Leader of Greater China Healthcare Practice McKinsey & Co. Richard Yeh Research analyst Citigroup Ingrid Zhang Head of Specialty Business Novartis Pharma Greater China Yan Che Strategy Management Bayer Guohong Shan General Manager, Specialty Care Business Unit Pfizer 12:15-1:00PM In Depth: Understanding the Beta Pharma/Amgen Joint Venture James Li, MD (Invited) Vice President and General Manager, Greater China Amgen

1:00-3:00PM KEYNOTE PANEL Big Pharma GMs Present A View From the Top (Includes 30 minutes for buffet lunch) This panel is designed to sum up the themes discussed the previous two days, bringing together three top China biopharma GMs, who will each provide an overview of their incountry strategies. In the moderated discussion that follows, we ll explore commonalities and differences in those strategies and ask participants how priorities are changing to meet the evolving needs of a rapidly changing China. Tamra Sami (moderator) Managing Editor, PharmAsia News Elsevier Business Intelligence Thad Huston President Xian Janssen Pharmaceutical Ltd. Johnson & Johnson Jean-Christophe Pointeau President Bristol-Myers Squibb China & Sino-American Shanghai Squibb (SASS) David Snow President, China and Hong Kong AstraZeneca 3:00PM Closing Comments: See You in 2014!

Organizing Committee Chairman Steve Yang, PhD VP, Head of Asia and Emerging Markets imed AstraZeneca Tony Zhang, PhD VP, External R&D, Asia Eli Lilly Jun Bao, PhD Director, WW Business Development Head of China GlaxoSmithKline Darren Ji, PhD Global Head of Partnering, Asia and Emerging Markets Roche George Baeder SVP Asia Pacific Consulting & China Commercial Quintiles Debra Yu, MD Managing Director Labrador Advisors Kewen Jin, PhD Principal Nimbus Innoworks Jay Dong General Manager Asia Pacific Cell Signal Technology Jimmy Zhang, PhD Greater China Lead, Licensing, Acquisitions and External Research WW Licensing and Acquisitions Merck and Co., Inc. Yun He Professor, Innovative Drug Research Center Chongqing University Franck Le Deu Partner, Leader of McKinsey Greater China Healthcare Practice McKinsey & Company Joshua Berlin Executive Editor & Director of Business Development Elsevier Business Intelligence Tamra Sami Managing Editor, PharmAsia News Elsevier Business Intelligence Daniel Poppy Associate Managing Bureau Editor, PharmAsia News Elsevier Business Intelligence Dai Jialing China Bureau Chief, PharmAsia News FDC Reports/ Elsevier Business Intelligence Brian Yang Senior Writer PharmAsia News